ALPHARETTA, Ga., April 29, 2019 (GLOBE NEWSWIRE) — Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”), the owner and operator of innovative medical technology products and services including Lung Health Institute and the DenerveX® System, today announced a series of new management appointments bolstering its management team following the recent appointment of Bill Horne as Chief Executive Officer.
“I’m pleased to welcome Jeremy, Ann, Briley and Gary to our management team. I am a firm believer that a company’s strongest assets are often its people. I handpicked this team after having had the privilege of working with them for many years previous where we together created a well-respected and highly profitable health care brand and organization. Ultimately, together we successfully grew the company in excess of $250M in annual revenues while generating very positive EBITDA. We created sizeable value for our investors which culminated with a sale of the company to a private equity firm,” said William “Bill” Horne, Medovex CEO and Chairman.
Horne continued, “I am again excited to be in the company of other executives who I know possess integrity and a strong work ethic. To again be in the company of my team, focused on leveraging our past success for the benefit of our current shareholders. I look forward to their formal appointment as corporate officers at our soon to be held board meeting, followed by updating shareholders on the strengthening underlying fundamentals of the company itself and how we together plan to build atop of recent operational momentum.”
The Company has named the following executives to its management team.
Chief Financial Officer — Jeremy Daniel
Jeremy Daniel is a top-performing, highly experienced financial, operations and strategic planning executive with broad-based expertise building and leading effective strategies for revenue production, operations management, financial and accounting systems, and team leadership in the health care industry.
Daniel served as the CFO of Regenerative Medicine Solutions since 2012 where he co-lead vision, strategy and execution for all facets of financial, operations, strategic planning and organizational development for this leading provider of marketing and business solutions for brands in the field of regenerative medicine, with a focus on serving as the management company for The Lung Institute. Daniel earned a Bachelor of Business Administration from the University of Cincinnati and his MBA from Xavier University.
Chief Operating Officer — Ann Miller
Ann Miller is the former Chief Operating Officer of Regenerative Medicine Solutions. In this role, she is focused on leading operations through research, evaluation and implementation of key business strategies to improve performance and organizational development as it relates to patient satisfaction, quality care standards and revenue.
Prior to joining RMS, Miller was the chief operating officer for Advanced Healthcare Partners and a director with Laser Spine Institute. She has been recognized as an Executive to Know by Becker’s ASC Review and Tampa Bay Business Journal as well as having received numerous recognition and awards from Modern Healthcare. Miller earned a bachelor’s degree in anthropology from Tulane University.
Chief Marketing Officer — Briley Cienkosz
Briley Cienkosz is the former Chief Marketing Officer of The Laser Spine Institute where she was responsible for its corporate brand, corporate communications and integrated marketing efforts. While at Laser Spine Institute, Cienkosz was an integral part of implementing the company’s first DRTV (direct response television) campaign, while also helping to launch four ambulatory surgery centers for the organization.
Cienkosz was named a Tampa Bay Business Journal Up & Comer in 2013 and a Tampa Bay Business Woman of the year in 2012. She earned a Bachelor of Science in marketing from Southern Illinois University and a Master of Business Administration from the University of Wisconsin.
Chief Relationship Officer — Gary Mancini
Gary Mancini is the former Vice President of Spine Care Services for Laser Spine Institute. Mancini’s natural ability to inspire others defines his management style. He has successfully created engaging strategies designed to teach and refresh employees’ knowledge of treatment options.
Mancini has also served as Vice Chairman of the Southwest Florida Charter School Board, a member of Leadership Tampa Bay and was named one of Becker’s ASC Rising Stars under 40. He earned a degree in finance and marketing from Florida State University.
About Medovex Corporation
Medovex Corporation was formed to acquire and develop a diversified portfolio of innovative medical technology products and services with the goal to improve the quality of life for patients. Based in Alpharetta, Georgia, Medovex’s first product, the DenerveX® System, is intended to provide long-lasting relief from pain associated with facet joint syndrome. In 2019, the Company acquired Regenerative Medicine Solutions, LLC, a Tampa, Florida-based biomedical services company that manages Lung Health Institute. Lung Health Institute is a leader in regenerative medicine that specializes in cellular therapies to treat chronic obstructive pulmonary disease (COPD) and other chronic lung diseases. For more information on Medovex, please visit www.medovex.com.
Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those outlined in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.